Program for 7th March 2008 |
| 07.00-08.30 |
Registration |
|
| 08.30-08.45 |
Opening session |
|
| 08.30-08.35 |
Welcome |
Hani Gabra, MD PhD |
| 08.35-08.40 |
Opening words |
Annwen Jones |
| 08.40-08.45 |
Address by the UK National Director of Cancer Services |
Mike Richards CBE, MD |
| 08.45-09.30 |
Key-note Lecture
"Sponsored by AICR - Association for International Cancer Research". |
|
| 08.45-09.30 |
Ovarian Cancer, now and the future |
Bob Bast, MD |
| 09.30-10.00 |
Key-note Lecture "Sponsored by Imperial
College London". |
|
| 09.30-10.00 |
Genome-Wide Target Discovery in Ovarian
Cancer |
Mike Birrer, MD PhD |
| 10.00-10.30 |
Break |
|
| 10.30-11.45 |
Session I: Biology of Ovarian Cancer |
Moderator: Mike Birrer, MD PhD |
| 10.30-10.50 |
Molecular evolution of ovarian cancer |
Jeff Boyd, PhD |
| 10.50-11.10 |
Loco-regional peritoneal dissemination |
Frances Balkwill, PhD |
| 11.10-11.30 |
Molecular classification |
Ralf Butzow, MD PhD |
| 11.30-11.45 |
Proffered papers |
|
| |
-OPCML interacts with ErB family members and abolishes
growth factor-induced autophosphorylation of the EGF-receptor |
Arthur B. McKie |
| |
-Integrative computational biology aproach leads to discovering
novel putative biomarkers for early ovarian cancer detection |
Igor Jurisica |
| 11.45-13.30 |
Session II Targets I
"Sponsored by AstraZeneca Oncology"
|
Moderator: Jonathan Ledermann, MD |
| 11.45-12.05 |
Src |
Margaret Frame, PhD |
| 12.05-12.25 |
Src inhibition in ovarian cancer |
Anil Sood, MD |
| 12.25-12.45 |
PARP inhibitors, biology and translational
development |
Andrew Tutt, MD |
| 12.45-13.05 |
Clinical developments of PARP inhibitors in
ovarian cancer |
Stan Kaye, MD |
| 13.05-13.30 |
Proffered papers |
|
| |
-Evaluation of the safety of the PARP-1 Inhibitor AG014699 in BRCA2
heterozygote models
|
Yvette Drew |
| |
-Targeting Inflammatory Cytokines using Adenoviruses – gene delivery
of biological therapies in ovarian cancer
|
Michael Salako |
| |
-The "BRCAness" Syndrome in ovarian cancer: a case control study
describing the clinical features and outcome of patients with epithelial ovarian
cancer associated with BRCA1 and BRCA2 mutations
|
Martin Gore |
| 13.30-14.30 |
Lunch & poster viewing |
|
| 14.30-16.05 |
Session III Targets II
"Sponsored by GSK Oncology"
|
Moderator: Martin Gore, MD PhD |
| 14.30-14.50 |
Angiogenesis – basic aspects |
Raffaella Giavazzi, MD PhD |
| 14.50-15.10 |
Clinical development of angiogenesis
inhibitors in ovarian cancer |
Gordon Jayson, MD PhD |
| 15.10-15.30 |
Epigenomics |
Robert Brown, PhD |
| 15.30-15.50 |
PI3K pathway |
Joseph Testa, PhD |
| 15.50-16.05 |
Proffered papers |
|
| |
-DNA Methylation of Stem Cell Polycombgroup Target Genes as
Independent Prognostic Markers in Ovarian Cancer
|
Martin Widschwendter |
| |
-Anti-VEGF Treatments in Epithelial Ovarian Cancer: is it only
anti-angiogenesis? |
Xuan Bich Trinh |
| 16.05-16.30 |
Break |
|
| 16.30-17.50 |
Session IV Molecular Profiling for new
Target Discovery
"Sponsored by Oxford Gene Technology" |
Moderator: David Bowtell, MD |
| 16.30-16.50 |
Survival Related Profile, Pathways and Transcription Factors in Ovarian Cancer |
Ate van der Zee, MD |
| 16.50-17.30 |
Proffered papers |
|
| |
-Pathway analysis identifies a possible role for inflammation and
extracellular matrix remodelling in platinum-based chemotherapy resistance in
ovarian cancer
|
Jozien Helleman |
| |
-Identification of determinants of acquired platinum-resistance from
clinically derived ovarian cancer model systems |
Euan Stronach |
| |
-The Genetic Profile of Ovarian Low Grade Serous Carcinoma is
similar to Serous Low Malignant Potential Tumors with Micropapillary Features
and distinct from High Grade Serous Carcinoma |
Taymaa May |
| |
-Molecular analysis of ovarian cancer |
David Bowtell |
| 17.30-17.50 |
What does this mean for clinical practice? |
James Brenton, MD PhD |
| 17.50-18.00 |
General session Questions & Answers |
Moderator: Hani Gabra, MD PhD |
Program for 8th March 2008 |
| 08.45-10.25 |
Session V Predictive and Prognostic
Markers |
Moderator: John Green, MD PhD |
| 08.45-09.05 |
The use of informatics to develop biomarker
candidates in ovarian cancer |
Lance Miller, PhD |
| 09.05-09.25 |
The use of PET as a predictive tool |
Eric Aboagye, PhD |
| 09.25-09.45 |
Ovarian cancer stem cells – myth or reality? |
Gabriella Ferrandina, MD |
| 09.45-10.05 |
How to predict surgical outcomes in
recurrent disease |
Philipp Harter, MD |
| 10.05-10.35 |
Proffered papers |
|
| |
-ERCC-1 gene expression as a predictor of outcome following
platinum-based chemotherapy in epithelial ovarian cancer (EOC) |
Caroline Michie |
| |
-Identification and isolation of normal and tumor ovarian epithelial
stem cells |
Alessandra Insinga |
| |
-Prevalence screen in the United Kingdom Collaborative Trial of
Ovarian Cancer Screening (UKCTOCS) |
Usha Menon |
| 10.35-11.05 |
Break |
|
| 11.05-13.25 |
Session VI The Challenge of Drug
Resistance
"Sponsored by Marshall Edwards"
|
Moderator: Stan Kaye, MD |
| 11.05-11.25 |
Introduction |
Stan Kaye, MD |
| 11.25-11.45 |
Partially platinum sensitive recurrence |
Nicoletta Colombo, MD |
| 11.45-12.05 |
Platinum resistant recurrence |
Eric Pujade-Lauraine, MD |
| 12.05-12.25 |
How to use new pathways to circumvent
platinum resistance? |
Elisabeth de Vries, MD PhD |
| 12.25-12.45 |
OVATURE: A clinical trial of platinum
resistance reversal |
Alan Husband, MD |
| 12.45-13.15 |
Proffered papers |
|
| |
-A novel mechanism for modulating paclitaxel response in ovarian
cancer
|
Ahmed Ashour Ahmed |
| |
-Metabolic profiling investigation of cisplatin sensitive and
resistant ovarian cancer cell lines by ¹H NMR spectroscopy |
Sophia Kelaini |
| |
-Oncolytic adenoviral mutants define a novel mode of programmed cell
death in ovarian cancer |
Iain McNeish |
| 13.15-14.15 |
Lunch & Poster viewing |
|
| 14.15-15.00 |
Key-note Lecture
“Sponsored by BACR – The British Association for Cancer Research” |
|
| 14.15-15.00 |
“Experiments in Translation” – Lessons from
GOG phase I and phase II studies |
Michael Bookman, MD |
| 15.00-16.00 |
Session VII Globalization |
Moderator: Christian Jackisch, MD |
| 15.00-15.20 |
International tissue banking in practice |
Jalid Sehouli, MD |
| 15.20-15.40 |
Are the endpoints in clinical trials right? |
Jacobus Pfisterer, MD PhD |
| 15.40-16.00 |
Towards a global ovarian cancer consortium –
Now and next steps |
David Bowtell, PhD |
| 16.00-16.30 |
General session Questions & Answers |
Moderator: Hani Gabra, MD PhD |
| 16.30-16.50 |
Towards the next meeting |
Allyson Kaye |